TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35985896

Group type: EXPERIMENTAL
Intervention: Feedback group (mHealth technology-assisted vocal training with real-time feedback on pitch, loudness, and duration)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (mHealth technology-assisted vocal training without real-time feedback)
Number of subjects: 23
Study: 32162438

Group type: EXPERIMENTAL
Intervention: Intralesional 2% zinc sulfate
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intralesional 2% vitamin D3
Number of subjects: 105

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 105
Study: 35918657

Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of vancomycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent infusion (II) of vancomycin
Number of subjects: 0
Study: 35442543

Group type: EXPERIMENTAL
Intervention: Atopalm cream® (twice-daily application for three consecutive years)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 200
Study: 33840310

Group type: EXPERIMENTAL
Intervention: Exposure to a news literacy video
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real-time user corrections to misinformation video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Promotional video
Number of subjects: 0
Study: 34018670

Group type: EXPERIMENTAL
Intervention: Standardized postoperative feeding protocol
Number of subjects: 81
Study: 32967742

Group type: EXPERIMENTAL
Intervention: 25 g of oral powder-based chocolate-flavoured CGMP for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference drink
Number of subjects: 24
Study: 32896172

Group type: EXPERIMENTAL
Intervention: Communication guide used by oncologists in the intervention group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Communication guide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33012641

Group type: EXPERIMENTAL
Intervention: 50% dose reduction of IAsp (2.6 ± 1.2 IU) before and after exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50% dose reduction of IAsp post-exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of 50% dose reduction of IAsp before and after exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Regular dose of IAsp (100%; 5.1 ± 2.4 IU)
Number of subjects: 16
Study: 33830440

Group type: EXPERIMENTAL
Intervention: PEG 3350 (0.7–1.5 mg/kg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lactulose (0.7–2.0 g/kg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PEG 3350
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 100
Study: 34596965

Group type: EXPERIMENTAL
Intervention: Arthroscopic debridement (35 patients)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Arthroscopic repair (43 patients)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Both groups (debridement and repair)
Number of subjects: 78
Study: 32388622

Group type: EXPERIMENTAL
Intervention: Oxytocin (40 IU intranasal)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Higher endogenous progesterone
Number of subjects: 112
Study: 35292378

Group type: EXPERIMENTAL
Intervention: Active TENS (n = 101)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo TENS (n = 99)
Number of subjects: 301

Group type: COMPARATOR
Intervention: No TENS (n = 99)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: RTO group
Number of subjects: 301
Study: 33208855

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) treatment for menopausal hot flushes, twice a day for four weeks
Number of subjects: 100
Study: 36273738

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (20 fractions of 20 Gy)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Conventional radiotherapy (30 fractions of 60 Gy)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: RapidPlan left hippocampus sparing model
Number of subjects: 133
Study: 34412521

Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg/d (n = 43)
Number of subjects: 84

Group type: COMPARATOR
Intervention: placebo (n = 41)
Number of subjects: 84
Study: 35040974

Group type: EXPERIMENTAL
Intervention: High-titer convalescent plasma
Number of subjects: 0
Study: 34134736

Group type: COMPARATOR
Intervention: Hearing for Learning Initiative (HfLI) - six 20-hour weeks of training over 3 months, including Certificate II in Aboriginal Primary Health Care and competencies in ear and hearing data collection, followed by part-time employment as Ear Health Facilitators.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hearing for Learning Initiative (HfLI)
Number of subjects: 18
Study: 35513301

Group type: EXPERIMENTAL
Intervention: 2-g cephazolin
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo (10-mL normal saline)
Number of subjects: 117
Study: 34496013

Group type: EXPERIMENTAL
Intervention: sarilumab
Number of subjects: 1362

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1362
Study: 35869554

Group type: EXPERIMENTAL
Intervention: modified Xiao-Feng Powder (mXFP) with antihistamine Bilastine
Number of subjects: 58

Group type: COMPARATOR
Intervention: placebo with antihistamine Bilastine
Number of subjects: 58
Study: 32604135

Group type: EXPERIMENTAL
Intervention: HEROS program
Number of subjects: 1929

Group type: COMPARATOR
Intervention: non-HEROS program
Number of subjects: 1929
Study: 34000661

Group type: EXPERIMENTAL
Intervention: Suspected Lynch syndrome-associated endometrial cancer
Number of subjects: 377

Group type: COMPARATOR
Intervention: Sporadic endometrial cancer
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES)
Number of subjects: 377
Study: 32891418

Group type: EXPERIMENTAL
Intervention: Pitavastatin/Fenofibrate combination therapy (2/160 mg)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Pitavastatin monotherapy (2 mg)
Number of subjects: 347
Study: 33024002

Group type: EXPERIMENTAL
Intervention: Expiratory positive airway pressure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Breath-stacking maneuver
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study: 32303867

Group type: EXPERIMENTAL
Intervention: Easy-to-hard training schedule
Number of subjects: 6

Group type: COMPARATOR
Intervention: Constant-hard training schedule
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: First trial performance
Number of subjects: 6
Study: 35156503

Group type: EXPERIMENTAL
Intervention: Motivational-educational songwriting (MESW)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Recreational music therapy (RMT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 134
Study: 32723201

Group type: EXPERIMENTAL
Intervention: Bright white light (414 lux)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Blue light (201 lux)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Dim darkened light (<2 lux)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Red light (235 lux)
Number of subjects: 49
Study: 33153482

Group type: EXPERIMENTAL
Intervention: Collaborative care psychosocial intervention (17-week program delivered at home by community health workers with tablet application)
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Enhanced usual care (control arm)
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Collaborative care psychosocial intervention
Number of subjects: 1440
Study: 34585598

Group type: EXPERIMENTAL
Intervention: del Nido cardioplegia (DN)
Number of subjects: 110

Group type: COMPARATOR
Intervention: cold blood cardioplegia (CB)
Number of subjects: 110
Study: 34852731

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hot-water immersion (HWI)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Passive resting
Number of subjects: 28
Study: 32492293

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 821
Study: 34240198

Group type: EXPERIMENTAL
Intervention: Veverimer
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 33792007

Group type: EXPERIMENTAL
Intervention: Six-strand locking multi-level repair
Number of subjects: 38

Group type: COMPARATOR
Intervention: Four-strand locking multi-level repair
Number of subjects: 38

Group type: COMPARATOR
Intervention: Two-strand locking multi-level repair
Number of subjects: 38
Study: 32877975

Group type: EXPERIMENTAL
Intervention: TKA
Number of subjects: 26
Study: 34563715

Group type: EXPERIMENTAL
Intervention: Vacuum Drains (VD)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Passive Drains (PD)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No Drains (ND)
Number of subjects: 78
Study: 35392739

Group type: EXPERIMENTAL
Intervention: Galcanezumab (240 mg loading dose, then 120 mg/month thereafter)
Number of subjects: 1022
Study: 32681228

Group type: EXPERIMENTAL
Intervention: Antibiotics/Hydroxychloroquine (ciprofloxacin 500 mg bd, doxycycline 100 mg bd, hydroxychloroquine 200 mg tds for 4 weeks, followed by doxycycline 100 mg bd and hydroxychloroquine 200 mg tds for 20 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Budesonide (Entocort CR 9 mg/day for 8 weeks, 6 mg/day for 2 weeks, 3 mg/day for 2 weeks)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Antibiotics/Hydroxychloroquine (including crossover)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Budesonide (including crossover)
Number of subjects: 59
Study: 32590001

Group type: EXPERIMENTAL
Intervention: Mixed lipid emulsion containing fish oil
Number of subjects: 230

Group type: COMPARATOR
Intervention: Soybean oil-based lipid emulsion
Number of subjects: 230
Study: 36045256

Group type: EXPERIMENTAL
Intervention: e-mobile training and consultancy services (mobile application) for 3 months post-operation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no e-mobile training and consultancy services)
Number of subjects: 51
Study: 33349506

Group type: EXPERIMENTAL
Intervention: Low functional health literacy (inadequate or marginal S-TOFHLA scores)
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Older age, male sex, lower reading level
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Higher S-TOFHLA scores
Number of subjects: 1066
Study: 35014600

Group type: EXPERIMENTAL
Intervention: Probiotic formula (strains Lactiplantibacillus plantarum KABP022, KABP023, KAPB033, plus strain Pediococcus acidilactici KABP021, totaling 2 × 10^9 CFU)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Probiotic formula
Number of subjects: 300
Study: 32877236

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 18
Study: 36125835

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) for 10 consecutive working days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 28
Study: 32472292

Group type: EXPERIMENTAL
Intervention: Taurine 3000 mg/daily for 8 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (crystalline microcellulose/daily for 8 weeks)
Number of subjects: 45
Study: 35545412

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.3 μg/(kg·h) (Dex1 group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 μg/(kg·h) (Dex2 group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex1 and Dex2 groups)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex2 group)
Number of subjects: 120
Study: 33217839

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion therapy (3 times a week for 3 menstrual cycles)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion therapy
Number of subjects: 246

Group type: COMPARATOR
Intervention: IVF-ET only
Number of subjects: 246
Study: 35501072

Group type: EXPERIMENTAL
Intervention: Sugammadex group
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 162
Study: 36221399

Group type: EXPERIMENTAL
Intervention: Bilateral endoscopic drainage with self-expanding metallic stents (SEMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trisegmental endoscopic drainage using self-expanding metallic stents (SEMS)
Number of subjects: 0
Study: 32574587

Group type: EXPERIMENTAL
Intervention: 300 mg dupilumab every 4 weeks + medium-potency topical corticosteroids (TCS)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Weight-based regimen of dupilumab every 2 weeks + medium-potency TCS
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo + medium-potency TCS
Number of subjects: 367
Study: 35132952

Group type: EXPERIMENTAL
Intervention: Attention Control Training (ACT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (ACT)
Number of subjects: 60
Study: 34193491

Group type: EXPERIMENTAL
Intervention: Patient-centred counselling and external adherence support for ART
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Patient-centred counselling and external adherence support for PrEP
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard counselling based on local HIV guidelines
Number of subjects: 300
Study: 32230954

Group type: EXPERIMENTAL
Intervention: Leucine (6 g/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (lactose, 6 g/day)
Number of subjects: 50
Study: 34666412

Group type: EXPERIMENTAL
Intervention: Capsiate (12 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (starch: 12 mg)
Number of subjects: 13
Study: 32036372

Group type: EXPERIMENTAL
Intervention: Hypertensive participants (1,349 out of 12,125, 11.1% of total population)
Number of subjects: 12125

Group type: COMPARATOR
Intervention: Normal weight participants
Number of subjects: 12125

Group type: COMPARATOR
Intervention: Overweight participants
Number of subjects: 12125

Group type: COMPARATOR
Intervention: Obese participants
Number of subjects: 12125

Group type: COMPARATOR
Intervention: All subjects
Number of subjects: 12125

Group type: EXPERIMENTAL
Intervention: Hypertensive participants
Number of subjects: 12125
Study: 33932162

Group type: EXPERIMENTAL
Intervention: Nicotine (6 mg) administered to cannabis users (CU)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo administered to cannabis users (CU)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-cannabis users (NU)
Number of subjects: 43
Study: 33516285

Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor therapy
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo to treatment group
Number of subjects: 239
Study: 32766331

Group type: EXPERIMENTAL
Intervention: Empowerment program based on social cognitive theory (SCT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 34371137

Group type: EXPERIMENTAL
Intervention: Assistance from caregivers
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Assistance from research staff
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Assistance from both caregivers and research staff
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Overall assistance in completing PROs
Number of subjects: 541
Study: 34688297

Group type: EXPERIMENTAL
Intervention: Lung Cancer Screening Decision Tool (LCSDecTool)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study: 32907824

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 18040

Group type: COMPARATOR
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 18040
Study: 32043288

Group type: COMPARATOR
Intervention: saxagliptin (5 mg/day) plus conventional therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: vitamin D3 (2000 IU/day) plus saxagliptin and conventional therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: conventional therapy with metformin (1-1.7 g/day) and/or insulin treatment
Number of subjects: 60
Study: 34293826

Group type: EXPERIMENTAL
Intervention: Multiple sclerosis (MS) patients
Number of subjects: 5548

Group type: EXPERIMENTAL
Intervention: Multiple sclerosis (MS) patients with comorbidities
Number of subjects: 5548

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 5548
Study: 33464732

Group type: EXPERIMENTAL
Intervention: Thetanix (Bacteroides thetaiotaomicron)
Number of subjects: 15
Study: 35001410

Group type: EXPERIMENTAL
Intervention: Concurrent training + placebo (CT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Saffron supplementation (S)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Concurrent training + saffron supplementation (CTS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 60
Study: 33848906

Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy (CIMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study: 34448951

Group type: EXPERIMENTAL
Intervention: Cone beam CT (CBCT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intraoral radiographs
Number of subjects: 60
Study: 33351194

Group type: EXPERIMENTAL
Intervention: High-flow nasal therapy at 2 l.kg-1.min-1
Number of subjects: 30

Group type: COMPARATOR
Intervention: High-flow nasal therapy at 4 l.kg-1.min-1
Number of subjects: 30
Study: 32527329

Group type: EXPERIMENTAL
Intervention: Skin cancer preventive behaviors (wearing sun-blocking clothing, using sunscreen cream, wearing a cap, using gloves and sunglasses)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Protection motivation theory and per capita income
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Response efficacy construct
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Per capita income
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Motivation
Number of subjects: 243
Study: 36151010

Group type: EXPERIMENTAL
Intervention: 40 Hz stimulation for four weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 4000 Hz stimulation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10,000 Hz stimulation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pooled analysis of 40 Hz and 4000 Hz
Number of subjects: 14
Study: 34259408

Group type: EXPERIMENTAL
Intervention: Refined moxibustion
Number of subjects: 150

Group type: COMPARATOR
Intervention: Box-moxibustion
Number of subjects: 150

Group type: COMPARATOR
Intervention: Chinese medication
Number of subjects: 150
Study: 36399383

Group type: EXPERIMENTAL
Intervention: Endurance training (END)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 68
Study: 34359996

Group type: EXPERIMENTAL
Intervention: MRI-defined medial perimeniscal synovitis
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Suprapatellar synovitis
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Higher concentration of serum C3M
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Higher concentration of serum CRPM
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Highest CRPM quartile
Number of subjects: 447
Study: 32470923

Group type: EXPERIMENTAL
Intervention: Beetroot juice (70-ml, containing ∼4.1 mmol of nitrate)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (70-ml, containing ∼0.04 mmol of nitrate)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Comparison between beetroot juice and placebo
Number of subjects: 70
Study: 34743579

Group type: EXPERIMENTAL
Intervention: Erenumab (70 or 140 mg/month)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Topiramate (50-100 mg/day)
Number of subjects: 777
Study: 33297409

Group type: EXPERIMENTAL
Intervention: Chlorogenic acids (CGAs) 270 mg tablets
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 33790860

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide or lanreotide monotherapy for ≥4 months
Number of subjects: 91
Study: 32183498

Group type: EXPERIMENTAL
Intervention: MPM
Number of subjects: 20

Group type: COMPARATOR
Intervention: β‐TCP
Number of subjects: 20
Study: 34773794

Group type: EXPERIMENTAL
Intervention: Tipifarnib
Number of subjects: 144

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 144
Study: 34494106

Group type: EXPERIMENTAL
Intervention: DHA (400 mg/d)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 112
Study: 32006087

Group type: EXPERIMENTAL
Intervention: Ethosuximide (500, 1000, or 1500 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ethosuximide (1500 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 35378119

Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS) of 2 mA for 15 min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 33259935

Group type: EXPERIMENTAL
Intervention: Palliative Volumetric Arc Therapy (VMAT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: 3-Dimensional Conventional Radiation Therapy (3DCRT)
Number of subjects: 69
Study: 32248594

Group type: EXPERIMENTAL
Intervention: Pilocarpine (1.54%) spray, used three times a day for 3 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pilocarpine (1.54%) spray
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33721085

Group type: EXPERIMENTAL
Intervention: Structured skills training group (SSTG) based on dialectical behavioural therapy
Number of subjects: 184

Group type: COMPARATOR
Intervention: Active control group based on psychoeducation
Number of subjects: 184

Group type: COMPARATOR
Intervention: Both groups (SSTG and control)
Number of subjects: 184
Study: 34672201

Group type: EXPERIMENTAL
Intervention: Pilates training program (36 sessions, 60 min each, 3 times a week for 12 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (maintained normal activities)
Number of subjects: 54
Study: 35653225

Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib and dexamethasone (Isa-Kd)
Number of subjects: 86